New AiCure and Tufts CSDD Research Sheds Light on Intentional Non-adherence

A recently published study from Tufts’ Center for the Study of Drug Development and AiCure, an AI and advanced data analytics company focused on improving clinical trials, identified and quantified the scope of intentional non-adherence to clinical trial drugs. The study, entitled “Assessing the Scope and Predictors of Intentional Dose Non-Adherence in Clinical Trials,” consisted of nearly 260,000 anonymized dosing results, which were drawn from 2,796 study volunteers participating in 23 different clinical trials of nine psychiatric, neurological and neuromuscular diseases.

To see the findings, click here.